Added to YB: 2024-08-28
Pitch date: 2024-06-30
MRUS [bullish]
Merus N.V.
+83.61%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.
Market Cap
$7.3B
Pitch Price
$52.79
Price Target
N/A
Dividend
N/A
EV/EBITDA
-17.68
P/E
-17.90
EV/Sales
114.35
Sector
Biotechnology
Category
growth
Show full summary:
Franklin Biotechnology Discovery Fund Portfolio Holding: Merus N.V.
MRUS: Clinical-stage biotech w/ promising peto data for head/neck cancer. Potential $3B+ peak sales. Best-in-class asset & unique antibody platform. Positive data could spark M&A interest. Pipeline focuses on multi-target antibodies (Biclonics/Triclonics). Blockbuster potential in oncology.
Read full article (1 min)